Sanofi (SNY)

NASDAQ: SNY · Real-Time Price · USD
48.30
-1.01 (-2.05%)
At close: Jul 3, 2025, 1:00 PM
48.47
+0.17 (0.35%)
After-hours: Jul 3, 2025, 4:47 PM EDT
-2.05%
Market Cap 118.17B
Revenue (ttm) 48.82B
Net Income (ttm) 6.81B
Shares Out 1.23B
EPS (ttm) 5.45
PE Ratio 17.36
Forward PE 10.04
Dividend $1.60 (3.31%)
Ex-Dividend Date May 9, 2025
Volume 1,555,525
Open 48.70
Previous Close 49.31
Day's Range 48.26 - 48.81
52-Week Range 45.80 - 60.12
Beta 0.41
Analysts Buy
Price Target 62.50 (+29.4%)
Earnings Date Jul 24, 2025

About SNY

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange NASDAQ
Ticker Symbol SNY
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial numbers in EUR Financial Statements

Analyst Summary

According to 2 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $62.5, which is an increase of 29.40% from the latest price.

Price Target
$62.5
(29.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Press release: Availability of the Q2 2025 Aide mémoire

Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quart...

3 days ago - GlobeNewsWire

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a poten...

3 days ago - GlobeNewsWire

Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts

New fund supports nonprofit partners working to address social drivers of health and strengthen community well-being CAMBRIDGE, Mass. , June 26, 2025 /PRNewswire/ -- Sanofi today announced it has awar...

7 days ago - PRNewsWire

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatme...

8 days ago - GlobeNewsWire

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bluep...

Other symbols: BPMC
13 days ago - Business Wire

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the elderly and is characterized by itchiness, blisters and lesions.

Other symbols: REGN
13 days ago - WSJ

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions...

Other symbols: REGN
13 days ago - GlobeNewsWire

RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports

U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, c...

Other symbols: MRKPFE
15 days ago - Reuters

RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury

A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used...

Other symbols: MRKPFE
15 days ago - CNBC

Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750 million fixed-...

16 days ago - GlobeNewsWire

SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $SNY--SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm.

17 days ago - Business Wire

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator...

Other symbols: REGN
18 days ago - GlobeNewsWire

Sanofi (SNY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Sanofi (NASDAQ:SNY) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 4:00 PM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care Conference Call Parti...

23 days ago - Seeking Alpha

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

Other symbols: BNTXMRNANVAXPFE
23 days ago - Barrons

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries...

4 weeks ago - GlobeNewsWire

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-bo...

4 weeks ago - GlobeNewsWire

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

Other symbols: BMYBNTXBPMCMRK
4 weeks ago - CNBC Television

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciar...

Other symbols: BPMC
4 weeks ago - GlobeNewsWire

Sanofi-Blueprint deal is a bullish signal about biotech M&A

The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. San...

Other symbols: BPMC
4 weeks ago - Yahoo Finance

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi

4 weeks ago - GlobeNewsWire

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio PARIS and CAMBRIDGE, Mass. , June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medi...

Other symbols: BPMC
4 weeks ago - PRNewsWire

Sanofi buys US biopharma group Blueprint in $9.1 bln deal

French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies s...

Other symbols: BPMC
4 weeks ago - Reuters

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.

Other symbols: BPMC
4 weeks ago - WSJ

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Other symbols: BPMC
4 weeks ago - GlobeNewsWire

Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment

Sanofi faces setbacks after itepekimab's Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Despite challenges, Sanofi is attractively valued, with my DCF anal...

4 weeks ago - Seeking Alpha